Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Monopar Therapeutics’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 2:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-016982
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $3,487,247 | $1,643,375 |
| General and administrative | 1,738,006 | 1,578,442 |
| Total operating expenses | 5,225,253 | 3,221,817 |
| Income (loss) from operations | (5,225,253) | (3,221,817) |
| Interest income (loss) | 1,332,203 | 596,845 |
| Net income (loss) | (3,893,050) | (2,624,972) |
| Other comprehensive income (loss): |
Document
FAQ
- What is Monopar Therapeutics's G&A?
- Monopar Therapeutics (MNPR) reported G&A of $1.74M in Q1 2026.
- How has Monopar Therapeutics's G&A changed year-over-year?
- Monopar Therapeutics's G&A increased by 10.1% year-over-year, from $1.58M to $1.74M.
- What is the long-term trend for Monopar Therapeutics's G&A?
- Over 4 years (2021 to 2025), Monopar Therapeutics's G&A has grown at a 26.8% compound annual growth rate (CAGR), from $2.63M to $6.8M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Monopar Therapeutics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude